NCT07154342View on ClinicalTrials.gov

A Study of IL4Rα Monoclonal Antibody in Patients With Seasonal Allergic Rhinitis

PHASE3RecruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

August 15, 2025

Primary Completion Date

April 30, 2026

Study Completion Date

July 31, 2026

Conditions
Allergic Rhinitis, Seasonal
Interventions
BIOLOGICAL

GR1802 injection

Recombinant fully human anti-IL4Rα monoclonal antibody drug.

BIOLOGICAL

Placebo

Placebo

Trial Locations (1)

430000

RECRUITING

Zhongnan Hospital of Wuhan university, Wuhan

All Listed Sponsors
lead

Genrix (Shanghai) Biopharmaceutical Co., Ltd.

INDUSTRY